+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Peptide contraception in women inhibition of ovulation by chronic intranasal lhrh agonist therapy

Peptide contraception in women inhibition of ovulation by chronic intranasal lhrh agonist therapy

Contraception 31(2): 111-118

Healthy female volunteers (71) used the LHRH superagonist D-Ser(TBU)6-EA10-L RH (buserelin) for contraception during 3-26 mo. One daily dose of 200-600 .mu.g was administered by the nasal route. No pregnancy occurred during the 628 treatment months. The bleeding pattern varied from fairly regular menstrual bleedings (n = 26) to oligomenorrhea (n = 27) and amenorrhea (n = 18). No severe or dysfunctional bleeding disturbances were observed. No signs of hyperplastic changes of the endometrium were found in 57 endometrial biopsies. After cessation of the long-term treatment normal ovulation and menstruation returned after 41.3 days, on average. Thus, intranasal administration of an LHRH agonist for inhibition of ovulation is a promising new contraceptive method for women.

(PDF 0-2 workdays service: $29.90)

Accession: 006079715

Download citation: RISBibTeXText

Related references

Peptide contraception in women. Inhibition of ovulation by chronic intranasal LRH agonist therapy. Upsala Journal of Medical Sciences 89(2): 99-106, 1984

Intranasal LHRH agonist treatment for inhibition of ovulation in women: clinical aspects. Clinical Endocrinology 17(1): 91-98, 1982

Peptide contraception 1 mechanisms behind the anti reproductive effects of chronic lhrh agonist treatment in women. Acta Obstetricia Et Gynecologica Scandinavica Supplement: 106-107, 1983

Inhibition of ovulation during discontinuous intranasal lhrh agonist dosing in combination with gestagen induced bleeding. Fertility & Sterility 43(6): 868-877, 1985

Peptide contraception by inhibition of ovulation with intranasal GnRH superagonist: clinical and metabolic aspects. Progress in Clinical and Biological Research 225: 337-351, 1986

Endometrial patterns in women on chronic lhrh agonist treatment for contraception. Fertility & Sterility 36(3): 339-342, 1981

Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results. Fertility and Sterility 45(5): 617-623, 1986

Intranasal LHRH agonist combined periodically with a progestogen for contraception. Advances in Contraception 5(4): 253-262, 1989

Intranasal LHRH agonist (Buserelin) after ovulation: a post-coital contraceptive approach. Contraceptive Delivery Systems 4(2): 107-125, 1983

Sequential administration of an intra nasal lhrh agonist and an oral progestogen for inhibition of ovulation and control of uterine bleeding in normal women. Acta Endocrinologica Supplementum 103(256): 75, 1983

Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist. Contraception 19(5): 497-506, 1979

Intranasal LRH-A for contraception by inhibition of ovulation: observation of 10 cases. Zhonghua Fu Chan Ke Za Zhi 22(1): 18-21, 61-2, 1987

Intranasal treatment with lhrh agonist in women with endometriosis. Journal of Steroid Biochemistry 20(6 PART B): 1403, 1984

Ovulation induction effects of intranasal administration of native lhrh to amenorrheic women. Japanese Journal of Fertility & Sterility 32(3): 96-101, 1987

Lhrh agonist for contraception in breast feeding women. Journal of Clinical Endocrinology & Metabolism 69(5): 996-1002, 1989